Expiring Drug Patents Cheat Sheet
We analyse the patents covering drugs in 134 countries and quickly give you the likely loss-of-exclusivity/generic entry date

Generic name: enzalutamide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 29, 2026
Generic Entry Controlled by: Canada Patent 2,608,436
Patent Title: COMPOSES DIARYLHYDANTOINES (DIARYLHYDANTOIN COMPOUNDS)

XTANDI is a drug marketed by Astellas. There are seven patents protecting this drug and one Paragraph IV challenge. Four tentatively approved generics are ready to enter the market.

This drug has one hundred and ninety-one patent family members in thirty-five countries. There has been litigation on patents covering XTANDI

See drug price trends for XTANDI.

The generic ingredient in XTANDI is enzalutamide. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the enzalutamide profile page.

Generic name: alcaftadine
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 31, 2026
Generic Entry Controlled by: Canada Patent 2,648,115
Patent Title: TRAITEMENTS DE L'ALLERGIE OCULAIRE (OCULAR ALLERGY TREATMENTS)

LASTACAFT is a drug marketed by Abbvie. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has forty-six patent family members in thirty countries. There has been litigation on patents covering LASTACAFT

See drug price trends for LASTACAFT.

The generic ingredient in LASTACAFT is alcaftadine. There are six drug master file entries for this API. Four suppliers are listed for this generic product. Additional details are available on the alcaftadine profile page.

Generic name: donepezil hydrochloride; memantine hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 06, 2026
Generic Entry Controlled by: Canada Patent 2,604,052
Patent Title: PROCEDES ET COMPOSITIONS POUR LE TRAITEMENT DES PATHOLOGIES ASSOCIEES AU SYSTEME NERVEUX CENTRAL (METHODS AND COMPOSITIONS FOR TREATMENT OF CNS DISORDERS)

NAMZARIC is a drug marketed by Abbvie. There are two patents protecting this drug and three Paragraph IV challenges. One tentatively approved generic is ready to enter the market.

This drug has sixty-seven patent family members in nineteen countries. There has been litigation on patents covering NAMZARIC

See drug price trends for NAMZARIC.

The generic ingredient in NAMZARIC is donepezil hydrochloride; memantine hydrochloride. There are thirty-two drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the donepezil hydrochloride; memantine hydrochloride profile page.

Generic name: lisdexamfetamine dimesylate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 10, 2026
Generic Entry Controlled by: Canada Patent 2,603,873
Patent Title: PROMEDICAMENTS A BASE D'AMPHETAMINE RESISTANTS A LA CONSOMMATION ABUSIVE (ABUSE-RESISTANT AMPHETAMINE PRODRUGS)

VYVANSE is a drug marketed by Takeda Pharms Usa.

This drug has sixty-seven patent family members in nineteen countries. There has been litigation on patents covering VYVANSE

See drug price trends for VYVANSE.

The generic ingredient in VYVANSE is lisdexamfetamine dimesylate. Twenty-one suppliers are listed for this generic product. Additional details are available on the lisdexamfetamine dimesylate profile page.

Generic name: testosterone undecanoate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 14, 2026
Generic Entry Controlled by: Canada Patent 2,604,943
Patent Title: SYSTEMES D'APPORT DE SUBSTANCES PHARMACEUTIQUES DESTINES A DES MEDICAMENTS HYDROPHOBES ET COMPOSITIONS COMPRENANT CES DERNIERS (PHARMACEUTICAL DELIVERY SYSTEMS FOR HYDROPHOBIC DRUGS AND COMPOSITIONS COMPRISING SAME)

JATENZO is a drug marketed by Tolmar. There are ten patents protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has twenty-nine patent family members in fourteen countries. There has been litigation on patents covering JATENZO

See drug price trends for JATENZO.

The generic ingredient in JATENZO is testosterone undecanoate. There are sixty-nine drug master file entries for this API. Four suppliers are listed for this generic product. Additional details are available on the testosterone undecanoate profile page.

Generic name: ethinyl estradiol; norethindrone acetate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 17, 2026
Generic Entry Controlled by: Canada Patent 2,605,299
Patent Title: REGIME CONTRACEPTIF DE DOSAGE D'ESTROGENES ETENDU (EXTENDED ESTROGEN DOSING CONTRACEPTIVE REGIMEN)

LO LOESTRIN FE is a drug marketed by Apil. There is one patent protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has nine patent family members in seven countries. There has been litigation on patents covering LO LOESTRIN FE

See drug price trends for LO LOESTRIN FE.

The generic ingredient in LO LOESTRIN FE is ethinyl estradiol; norethindrone acetate. There are twenty-six drug master file entries for this API. Twenty-five suppliers are listed for this generic product. Additional details are available on the ethinyl estradiol; norethindrone acetate profile page.

Generic name: ethinyl estradiol; norethindrone acetate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 17, 2026
Generic Entry Controlled by: Canada Patent 2,605,299
Patent Title: REGIME CONTRACEPTIF DE DOSAGE D'ESTROGENES ETENDU (EXTENDED ESTROGEN DOSING CONTRACEPTIVE REGIMEN)

LO MINASTRIN FE is a drug marketed by Apil. There is one patent protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has nine patent family members in seven countries. There has been litigation on patents covering LO MINASTRIN FE

The generic ingredient in LO MINASTRIN FE is ethinyl estradiol; norethindrone acetate. There are twenty-six drug master file entries for this API. Twenty-five suppliers are listed for this generic product. Additional details are available on the ethinyl estradiol; norethindrone acetate profile page.

Generic name: azelaic acid
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 18, 2026
Generic Entry Controlled by: Canada Patent 2,606,933
Patent Title: TROUSSE DE STEROIDES, COMPOSITION MOUSSANTE ET UTILISATIONS (STEROID KIT AND FOAMABLE COMPOSITION AND USES THEREOF)

FINACEA is a drug marketed by One tentatively approved generic is ready to enter the market.

This drug has one hundred and thirty-seven patent family members in twenty countries. There has been litigation on patents covering FINACEA

See drug price trends for FINACEA .

The generic ingredient in FINACEA is azelaic acid. There are eight drug master file entries for this API. Eight suppliers are listed for this generic product. Additional details are available on the azelaic acid profile page.

Generic name: lapatinib ditosylate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 18, 2026
Generic Entry Controlled by: Canada Patent 2,606,207
Patent Title: PREPARATION PHARMACEUTIQUE (PHARMACEUTICAL COMPOSITION)

TYKERB is a drug marketed by Novartis. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has twenty-eight patent family members in twenty-six countries.

See drug price trends for TYKERB.

The generic ingredient in TYKERB is lapatinib ditosylate. There are seven drug master file entries for this API. Four suppliers are listed for this generic product. Additional details are available on the lapatinib ditosylate profile page.

Generic name: eslicarbazepine acetate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 21, 2026
Generic Entry Controlled by: Canada Patent 2,616,984
Patent Title: REDUCTION CATALYTIQUE ASYMETRIQUE D'OXCARBAZEPINE (ASYMMETRIC CATALYTIC REDUCTION OF OXCARBAZEPINE)

APTIOM is a drug marketed by Sumitomo Pharma Am. There are seven patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has ninety-three patent family members in twenty-six countries. There has been litigation on patents covering APTIOM

See drug price trends for APTIOM.

The generic ingredient in APTIOM is eslicarbazepine acetate. There are twelve drug master file entries for this API. Eight suppliers are listed for this generic product. Additional details are available on the eslicarbazepine acetate profile page.

Generic name: cenobamate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 21, 2026
Generic Entry Controlled by: Canada Patent 2,606,258
Patent Title: COMPOSES AZOLE NEUROTHERAPEUTIQUES (NEUROTHERAPEUTIC AZOLE COMPOUNDS)

XCOPRI is a drug marketed by Sk Life. There are two patents protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has twenty-six patent family members in twenty countries. There has been litigation on patents covering XCOPRI

See drug price trends for XCOPRI.

The generic ingredient in XCOPRI is cenobamate. One supplier is listed for this generic product. Additional details are available on the cenobamate profile page.

Generic name: treprostinil diolamine
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 27, 2026
Generic Entry Controlled by: Canada Patent 2,649,243
Patent Title: DISPOSITIF D'ADMINISTRATION D'UN MEDICAMENT OSMOTIQUE (AN OSMOTIC DRUG DELIVERY SYSTEM)

ORENITRAM is a drug marketed by United Therap. There are nine patents protecting this drug and two Paragraph IV challenges.

This drug has fifty-nine patent family members in eight countries. There has been litigation on patents covering ORENITRAM

See drug price trends for ORENITRAM.

The generic ingredient in ORENITRAM is treprostinil diolamine. There are nineteen drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the treprostinil diolamine profile page.

Generic name: cabotegravir sodium
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 28, 2026
Generic Entry Controlled by: Canada Patent 2,606,282
Patent Title: DERIVE POLYCYCLIQUE DE LA CARBAMOYLPYRIDONE A ACTIVITE INHIBITRICE SUR L'INTEGRASE DU VIH (POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASEINHIBITORY ACTIVITY)

VOCABRIA is a drug marketed by Viiv Hlthcare. There are two patents protecting this drug.

This drug has one hundred and twenty-six patent family members in thirty-three countries.

The generic ingredient in VOCABRIA is cabotegravir sodium. One supplier is listed for this generic product. Additional details are available on the cabotegravir sodium profile page.

Generic name: linagliptin
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 04, 2026
Generic Entry Controlled by: Canada Patent 2,649,922

TRADJENTA is a drug marketed by Boehringer Ingelheim. There are ten patents protecting this drug and one Paragraph IV challenge. Three tentatively approved generics are ready to enter the market.

This drug has three hundred and eighty-one patent family members in forty-one countries. There has been litigation on patents covering TRADJENTA

See drug price trends for TRADJENTA.

The generic ingredient in TRADJENTA is linagliptin. There are nineteen drug master file entries for this API. Four suppliers are listed for this generic product. Additional details are available on the linagliptin profile page.

Generic name: azelaic acid
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 08, 2026
Generic Entry Controlled by: Canada Patent 2,609,948
Patent Title: TROUSSE ET COMPOSITION VASOACTIVE ET LEURS UTILISATIONS (VASOACTIVE KIT AND COMPOSITION AND USES THEREOF)

FINACEA is a drug marketed by One tentatively approved generic is ready to enter the market.

This drug has one hundred and thirty-seven patent family members in twenty countries. There has been litigation on patents covering FINACEA

See drug price trends for FINACEA .

The generic ingredient in FINACEA is azelaic acid. There are eight drug master file entries for this API. Eight suppliers are listed for this generic product. Additional details are available on the azelaic acid profile page.

Generic name: azelaic acid
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 09, 2026
Generic Entry Controlled by: Canada Patent 2,609,953
Patent Title: COMPOSITIONS EXPANSIBLES SACCHARIDIQUES (SACCHARIDE FOAMABLE COMPOSITIONS)

FINACEA is a drug marketed by One tentatively approved generic is ready to enter the market.

This drug has one hundred and thirty-seven patent family members in twenty countries. There has been litigation on patents covering FINACEA

See drug price trends for FINACEA .

The generic ingredient in FINACEA is azelaic acid. There are eight drug master file entries for this API. Eight suppliers are listed for this generic product. Additional details are available on the azelaic acid profile page.

Generic name: azelaic acid
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 09, 2026
Generic Entry Controlled by: Canada Patent 2,610,662
Patent Title: EXCIPIENT EXPANSIBLE ET COMPOSITIONS PHARMACEUTIQUES CONTENANT CELUI-CI (FOAMABLE VEHICLE AND PHARMACEUTICAL COMPOSITIONS THEREOF)

FINACEA is a drug marketed by One tentatively approved generic is ready to enter the market.

This drug has one hundred and thirty-seven patent family members in twenty countries. There has been litigation on patents covering FINACEA

See drug price trends for FINACEA .

The generic ingredient in FINACEA is azelaic acid. There are eight drug master file entries for this API. Eight suppliers are listed for this generic product. Additional details are available on the azelaic acid profile page.

Generic name: belinostat
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 11, 2026
Generic Entry Controlled by: Canada Patent 2,606,598
Patent Title: FORMULATIONS PHARMACEUTIQUES D'INHIBITEURS DE HDAC (PHARMACEUTICAL FORMULATIONS OF HDAC INHIBITORS)

BELEODAQ is a drug marketed by Acrotech Biopharma. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has fifty-nine patent family members in twenty-seven countries. There has been litigation on patents covering BELEODAQ

See drug price trends for BELEODAQ.

The generic ingredient in BELEODAQ is belinostat. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the belinostat profile page.

Generic name: bosentan
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 15, 2026
Generic Entry Controlled by: Canada Patent 2,607,098
Patent Title: COMPRIME DISPERSIBLE (DISPERSIBLE BOSERTAN TABLET)

TRACLEER is a drug marketed by Actelion. There are two patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has twenty-eight patent family members in twenty-three countries. There has been litigation on patents covering TRACLEER

See drug price trends for TRACLEER.

The generic ingredient in TRACLEER is bosentan. There are nineteen drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the bosentan profile page.

Generic name: lurasidone hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 26, 2026
Generic Entry Controlled by: Canada Patent 2,606,510
Patent Title: COMPOSITION PHARMACEUTIQUE (PHARMACEUTICAL COMPOSITION)

LATUDA is a drug marketed by Sunovion Pharms Inc. There are six patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has forty-four patent family members in twenty-two countries. There has been litigation on patents covering LATUDA

See drug price trends for LATUDA.

The generic ingredient in LATUDA is lurasidone hydrochloride. There are twenty-six drug master file entries for this API. Twenty-nine suppliers are listed for this generic product. Additional details are available on the lurasidone hydrochloride profile page.

Generic name: boceprevir
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 31, 2026
Generic Entry Controlled by: Canada Patent 2,611,155
Patent Title: FORMULATIONS PHARMACEUTIQUES ET METHODES DE TRAITEMENT UTILISANT CES FORMULATIONS (COMBINATION OF HCV PROTEASE INHIBITORS WITH A SURFACTANT)

VICTRELIS is a drug marketed by Merck Sharp Dohme. There are two patents protecting this drug.

This drug has twenty-seven patent family members in seventeen countries.

The generic ingredient in VICTRELIS is boceprevir. Additional details are available on the boceprevir profile page.

Generic name: peginesatide acetate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 05, 2026
Generic Entry Controlled by: Canada Patent 2,609,401
Patent Title: PREPARATIONS DE PEPTIDES AGONISTES DU RECEPTEUR DE L'ERYTHROPOIETINE ET UTILISATIONS (ERYTHROPOIETIN RECEPTOR PEPTIDE FORMULATIONS AND USES)

OMONTYS is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug.

This drug has twenty-seven patent family members in eighteen countries.

The generic ingredient in OMONTYS is peginesatide acetate. Additional details are available on the peginesatide acetate profile page.

Generic name: azelaic acid
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 07, 2026
Generic Entry Controlled by: Canada Patent 2,611,577
Patent Title: KIT ET COMPOSITION ANTIBIOTIQUES ET LEURS UTILISATIONS (ANTIBIOTIC KIT AND COMPOSITION AND USES THEREOF)

FINACEA is a drug marketed by One tentatively approved generic is ready to enter the market.

This drug has one hundred and thirty-seven patent family members in twenty countries. There has been litigation on patents covering FINACEA

See drug price trends for FINACEA .

The generic ingredient in FINACEA is azelaic acid. There are eight drug master file entries for this API. Eight suppliers are listed for this generic product. Additional details are available on the azelaic acid profile page.

Generic name: vortioxetine hydrobromide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 16, 2026
Generic Entry Controlled by: Canada Patent 2,684,571
Patent Title: NOUVELLES UTILISATIONS THERAPEUTIQUES DE 1-[2-(2,4-DIMETHYLPHENYLSULFANYL)PHENYL]PIPERAZINE (NOVEL THERAPEUTIC USES OF 1-[2-(2,4-DIMETHYLPHENYLSULFANYL)PHENYL]-PIPE RAZINE)

TRINTELLIX is a drug marketed by Takeda Pharms Usa. There are ten patents protecting this drug and one Paragraph IV challenge. Three tentatively approved generics are ready to enter the market.

This drug has two hundred and seventeen patent family members in forty-two countries. There has been litigation on patents covering TRINTELLIX

See drug price trends for TRINTELLIX.

The generic ingredient in TRINTELLIX is vortioxetine hydrobromide. There are sixteen drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the vortioxetine hydrobromide profile page.

Generic name: morphine sulfate; naltrexone hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 19, 2026
Generic Entry Controlled by: Canada Patent 2,655,835

EMBEDA is a drug marketed by Alpharma Pharms. There are seven patents protecting this drug and four Paragraph IV challenges.

This drug has seventy-four patent family members in twenty-three countries.

See drug price trends for EMBEDA.

The generic ingredient in EMBEDA is morphine sulfate; naltrexone hydrochloride. There are twenty-three drug master file entries for this API. Additional details are available on the morphine sulfate; naltrexone hydrochloride profile page.

Generic name: ferric pyrophosphate citrate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 20, 2026
Generic Entry Controlled by: Canada Patent 2,550,493
Patent Title: EMBALLAGE DU PYROPHOSPHATE FERRIQUE POUR DIALYSE (PACKAGING OF FERRIC PYROPHOSPHATE FOR DIALYSIS)

TRIFERIC is a drug marketed by Rockwell Medical Inc. There are two patents protecting this drug.

This drug has thirteen patent family members in eleven countries.

See drug price trends for TRIFERIC.

The generic ingredient in TRIFERIC is ferric pyrophosphate citrate. There are twenty drug master file entries for this API. Additional details are available on the ferric pyrophosphate citrate profile page.

Generic name: aliskiren hemifumarate; hydrochlorothiazide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 23, 2026
Generic Entry Controlled by: Canada Patent 2,654,872

TEKTURNA HCT is a drug marketed by Noden Pharma. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has thirty-two patent family members in twenty-five countries. There has been litigation on patents covering TEKTURNA HCT

See drug price trends for TEKTURNA HCT.

The generic ingredient in TEKTURNA HCT is aliskiren hemifumarate; hydrochlorothiazide. There are four drug master file entries for this API. Additional details are available on the aliskiren hemifumarate; hydrochlorothiazide profile page.

Generic name: bupropion hydrobromide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 27, 2026
Generic Entry Controlled by: Canada Patent 2,578,626
Patent Title: FORMULATIONS A LIBERATION MODIFIEE D'UN SEL DE BUPROPION (MODIFIED-RELEASE FORMULATIONS OF A BUPROPION SALT)

APLENZIN is a drug marketed by Bausch. There are eight patents protecting this drug and three Paragraph IV challenges. One tentatively approved generic is ready to enter the market.

This drug has fifty-two patent family members in eighteen countries. There has been litigation on patents covering APLENZIN

See drug price trends for APLENZIN.

The generic ingredient in APLENZIN is bupropion hydrobromide. There are thirty-eight drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the bupropion hydrobromide profile page.

Generic name: amlodipine besylate; hydrochlorothiazide; valsartan
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 27, 2026
Generic Entry Controlled by: Canada Patent 2,654,986

EXFORGE HCT is a drug marketed by Novartis.

This drug has fifty-two patent family members in eighteen countries. There has been litigation on patents covering EXFORGE HCT

See drug price trends for EXFORGE HCT.

The generic ingredient in EXFORGE HCT is amlodipine besylate; hydrochlorothiazide; valsartan. There are fifty drug master file entries for this API. Five suppliers are listed for this generic product. Additional details are available on the amlodipine besylate; hydrochlorothiazide; valsartan profile page.

Generic name: bosutinib monohydrate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 28, 2026
Generic Entry Controlled by: Canada Patent 2,613,053
Patent Title: FORMES CRISTALLINES DE 4-[(2,4-DICHLORO-5-METHOXYPHENYL)AMINO]-6-METHOXY-7-[3-(4-METHYL-1-PIPERAZINYL)PROPOXY]-3-QUINOLINECARB-ONITRILE,ET LEURS PROCEDES DE PREPARATION (CRYSTALLINE FORMS OF 4-[(2,4-DICHLORO-5-METHOXYPHENYL)AMINO]-6-METHOXY-7-[3-(4-METHYL-1-PIPERAZINYL)PROPOXY]-3-QUINOLINECARBONITRILE ANDMETHODS OF PREPARING THE SAME)

BOSULIF is a drug marketed by Pf Prism Cv. There are four patents protecting this drug and two Paragraph IV challenges. Three tentatively approved generics are ready to enter the market.

This drug has eighty-one patent family members in thirty countries. There has been litigation on patents covering BOSULIF

See drug price trends for BOSULIF.

The generic ingredient in BOSULIF is bosutinib monohydrate. There are five drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the bosutinib monohydrate profile page.

Generic name: exenatide synthetic
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 28, 2026
Generic Entry Controlled by: Canada Patent 2,653,344

BYDUREON is a drug marketed by Astrazeneca Ab. There are seven patents protecting this drug.

This drug has three hundred and seven patent family members in forty-eight countries. There has been litigation on patents covering BYDUREON

See drug price trends for BYDUREON.

The generic ingredient in BYDUREON is exenatide synthetic. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the exenatide synthetic profile page.

Generic name: exenatide synthetic
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 28, 2026
Generic Entry Controlled by: Canada Patent 2,924,318

BYDUREON is a drug marketed by Astrazeneca Ab. There are seven patents protecting this drug.

This drug has three hundred and seven patent family members in forty-eight countries. There has been litigation on patents covering BYDUREON

See drug price trends for BYDUREON.

The generic ingredient in BYDUREON is exenatide synthetic. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the exenatide synthetic profile page.

Generic name: dapagliflozin
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 28, 2026
Generic Entry Controlled by: Canada Patent 2,653,344

FARXIGA is a drug marketed by Astrazeneca Ab. There are seventeen patents protecting this drug and one Paragraph IV challenge. Nineteen tentatively approved generics are ready to enter the market.

This drug has four hundred and twenty-three patent family members in fifty-two countries. There has been litigation on patents covering FARXIGA

See drug price trends for FARXIGA.

The generic ingredient in FARXIGA is dapagliflozin. There are twenty-six drug master file entries for this API. Five suppliers are listed for this generic product. Additional details are available on the dapagliflozin profile page.

Generic name: dapagliflozin
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 28, 2026
Generic Entry Controlled by: Canada Patent 2,924,318

FARXIGA is a drug marketed by Astrazeneca Ab. There are seventeen patents protecting this drug and one Paragraph IV challenge. Nineteen tentatively approved generics are ready to enter the market.

This drug has four hundred and twenty-three patent family members in fifty-two countries. There has been litigation on patents covering FARXIGA

See drug price trends for FARXIGA.

The generic ingredient in FARXIGA is dapagliflozin. There are twenty-six drug master file entries for this API. Five suppliers are listed for this generic product. Additional details are available on the dapagliflozin profile page.

Generic name: dapagliflozin; saxagliptin hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 28, 2026
Generic Entry Controlled by: Canada Patent 2,653,344

QTERN is a drug marketed by Astrazeneca Ab. There are seven patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and fifty-six patent family members in forty-eight countries. There has been litigation on patents covering QTERN

See drug price trends for QTERN.

The generic ingredient in QTERN is dapagliflozin; saxagliptin hydrochloride. There are twenty-six drug master file entries for this API. Additional details are available on the dapagliflozin; saxagliptin hydrochloride profile page.

Generic name: dapagliflozin; saxagliptin hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 28, 2026
Generic Entry Controlled by: Canada Patent 2,924,318

QTERN is a drug marketed by Astrazeneca Ab. There are seven patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and fifty-six patent family members in forty-eight countries. There has been litigation on patents covering QTERN

See drug price trends for QTERN.

The generic ingredient in QTERN is dapagliflozin; saxagliptin hydrochloride. There are twenty-six drug master file entries for this API. Additional details are available on the dapagliflozin; saxagliptin hydrochloride profile page.

Generic name: adapalene; benzoyl peroxide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 13, 2026
Generic Entry Controlled by: Canada Patent 2,656,456

EPIDUO is a drug marketed by Galderma Labs Lp and Galderma LabsThere are three patents protecting this drug and two Paragraph IV challenges.

This drug has thirty-five patent family members in twenty-two countries. There has been litigation on patents covering EPIDUO

See drug price trends for EPIDUO.

The generic ingredient in EPIDUO is adapalene; benzoyl peroxide. There are twelve drug master file entries for this API. Twelve suppliers are listed for this generic product. Additional details are available on the adapalene; benzoyl peroxide profile page.

Generic name: adapalene; benzoyl peroxide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 13, 2026
Generic Entry Controlled by: Canada Patent 2,656,456

EPIDUO FORTE is a drug marketed by Galderma Labs.

This drug has thirty-five patent family members in twenty-two countries. There has been litigation on patents covering EPIDUO FORTE

See drug price trends for EPIDUO FORTE.

The generic ingredient in EPIDUO FORTE is adapalene; benzoyl peroxide. There are twelve drug master file entries for this API. Twelve suppliers are listed for this generic product. Additional details are available on the adapalene; benzoyl peroxide profile page.

Generic name: methotrexate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 21, 2026
Generic Entry Controlled by: Canada Patent 2,659,662

RASUVO is a drug marketed by Medexus. There is one patent protecting this drug.

This drug has twenty-nine patent family members in twenty-one countries. There has been litigation on patents covering RASUVO

See drug price trends for RASUVO.

The generic ingredient in RASUVO is methotrexate. There are twenty drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the methotrexate profile page.

Generic name: methotrexate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 21, 2026
Generic Entry Controlled by: Canada Patent 2,869,671

RASUVO is a drug marketed by Medexus. There is one patent protecting this drug.

This drug has twenty-nine patent family members in twenty-one countries. There has been litigation on patents covering RASUVO

See drug price trends for RASUVO.

The generic ingredient in RASUVO is methotrexate. There are twenty drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the methotrexate profile page.

Generic name: simeprevir sodium
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 28, 2026
Generic Entry Controlled by: Canada Patent 2,616,580
Patent Title: INHIBITEURS MACROCYCLIQUES DU VIRUS DE L'HEPATITE C (MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS)

OLYSIO is a drug marketed by Janssen Prods. There are eight patents protecting this drug.

This drug has sixty-four patent family members in forty-one countries.

See drug price trends for OLYSIO.

The generic ingredient in OLYSIO is simeprevir sodium. There is one drug master file entry for this API. Additional details are available on the simeprevir sodium profile page.

Generic name: benzoyl peroxide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 02, 2026
Generic Entry Controlled by: Canada Patent 2,617,681
Patent Title: REVETEMENT PAR UN OXYDE METALLIQUE D'INGREDIENTS HYDROINSOLUBLES (METAL OXIDE COATING OF WATER INSOLUBLE INGREDIENTS)

EPSOLAY is a drug marketed by Mayne Pharma. There are fourteen patents protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has fifty-one patent family members in fifteen countries. There has been litigation on patents covering EPSOLAY

See drug price trends for EPSOLAY.

The generic ingredient in EPSOLAY is benzoyl peroxide. There are seventeen drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the benzoyl peroxide profile page.

Generic name: menthol; methyl salicylate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 04, 2026
Generic Entry Controlled by: Canada Patent 2,652,220
Patent Title: PREPARATION ADHESIVE COMPORTANT DU SALICYLATE DE METHYLE POUR ABSORPTION PERCUTANEE (ADHESIVE PREPARATION COMPRISING METHYL SALICYLATE FOR PERCUTANEOUS ABSORPTION)

SALONPAS is a drug marketed by Hisamitsu Pharm Co. There are two patents protecting this drug.

This drug has twenty patent family members in sixteen countries.

The generic ingredient in SALONPAS is menthol; methyl salicylate. There are eighteen drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the menthol; methyl salicylate profile page.

Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 15, 2026
Generic Entry Controlled by: Canada Patent 2,619,475
Patent Title: COMPOSITIONS PHARMACEUTIQUES A LIBERATION CONTROLEE DESTINEES A DES MEDICAMENTS ACIDO-LABILES (CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS FOR ACID LABILE DRUGS)

CREON is a drug marketed by

This drug has twenty patent family members in sixteen countries.

See drug price trends for CREON.

The generic ingredient in CREON is pancrelipase (amylase;lipase;protease). There are six drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.

Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 15, 2026
Generic Entry Controlled by: Canada Patent 2,619,477
Patent Title: NOYAUX CONSTITUES DE MICROGRANULES DE PANCREATINE ADAPTES A UN ENROBAGE ENTERIQUE (PANCREATIN MICROPELLET CORES SUITABLE FOR ENTERIC COATING)

CREON is a drug marketed by

This drug has twenty patent family members in sixteen countries.

See drug price trends for CREON.

The generic ingredient in CREON is pancrelipase (amylase;lipase;protease). There are six drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.

Generic name: crisaborole
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 16, 2026
Generic Entry Controlled by: Canada Patent 2,635,680
Patent Title: PETITES MOLECULES CONTENANT DU BORE (BORON-CONTAINING SMALL MOLECULES)

EUCRISA is a drug marketed by Anacor Pharms Inc. There are four patents protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has one hundred and forty-eight patent family members in twenty-eight countries. There has been litigation on patents covering EUCRISA

See drug price trends for EUCRISA.

The generic ingredient in EUCRISA is crisaborole. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the crisaborole profile page.

Generic name: tavaborole
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 16, 2026
Generic Entry Controlled by: Canada Patent 2,635,680
Patent Title: PETITES MOLECULES CONTENANT DU BORE (BORON-CONTAINING SMALL MOLECULES)

KERYDIN is a drug marketed by Anacor Pharms Inc.

This drug has one hundred and forty-eight patent family members in twenty-eight countries. There has been litigation on patents covering KERYDIN

See drug price trends for KERYDIN.

The generic ingredient in KERYDIN is tavaborole. There are six drug master file entries for this API. Seven suppliers are listed for this generic product. Additional details are available on the tavaborole profile page.

Generic name: ferric citrate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 18, 2026
Generic Entry Controlled by: Canada Patent 2,619,591
Patent Title: COMPOSES ORGANIQUES FERRIQUES DE QUALITE PHARMACEUTIQUE AINSI QU'UTILISATION DE CEUX-CI ET PROCEDES DE FABRICATION DE CEUX-CI (PHARMACEUTICAL-GRADE FERRIC ORGANIC COMPOUNDS, USES THEREOF AND METHODS OF MAKING SAME)

AURYXIA is a drug marketed by Keryx Biopharms. There are three patents protecting this drug.

This drug has one hundred and twenty-two patent family members in twenty-three countries. There has been litigation on patents covering AURYXIA

See drug price trends for AURYXIA.

The generic ingredient in AURYXIA is ferric citrate. There are twenty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the ferric citrate profile page.

Generic name: ferric citrate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 18, 2026
Generic Entry Controlled by: Canada Patent 3,050,453
Patent Title: COMPOSES ORGANIQUES FERRIQUES DE QUALITE PHARMACEUTIQUE AINSI QU'UTILISATION DE CEUX-CI ET PROCEDES DE FABRICATION DE CEUX-CI (PHARMACEUTICAL-GRADE FERRIC ORGANIC COMPOUNDS, USES THEREOF AND METHODS OF MAKING SAME)

AURYXIA is a drug marketed by Keryx Biopharms. There are three patents protecting this drug.

This drug has one hundred and twenty-two patent family members in twenty-three countries. There has been litigation on patents covering AURYXIA

See drug price trends for AURYXIA.

The generic ingredient in AURYXIA is ferric citrate. There are twenty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the ferric citrate profile page.

Generic name: hydrocodone bitartrate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: September 15, 2026
Generic Entry Controlled by: Canada Patent 2,663,172
Patent Title: PREPARATION MEDICAMENTEUSE EMPECHANT L'UTILISATION ABUSIVE (ABUSE RESISTANT DRUG FORMULATION)

VANTRELA ER is a drug marketed by Teva Branded Pharm. There are three patents protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has thirty-three patent family members in thirteen countries. There has been litigation on patents covering VANTRELA ER

The generic ingredient in VANTRELA ER is hydrocodone bitartrate. There are twenty-three drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the hydrocodone bitartrate profile page.

Generic name: hydrocodone bitartrate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: September 15, 2026
Generic Entry Controlled by: Canada Patent 2,699,142
Patent Title: FORMULATION MEDICAMENTEUSE CONTRE L'ABUS (ABUSE RESISTANT DRUG FORMULATION)

VANTRELA ER is a drug marketed by Teva Branded Pharm. There are three patents protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has thirty-three patent family members in thirteen countries. There has been litigation on patents covering VANTRELA ER

The generic ingredient in VANTRELA ER is hydrocodone bitartrate. There are twenty-three drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the hydrocodone bitartrate profile page.

Generic name: pirfenidone
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: September 22, 2026
Generic Entry Controlled by: Canada Patent 2,620,380

ESBRIET is a drug marketed by Legacy Pharma. There are twenty patents protecting this drug and two Paragraph IV challenges. One tentatively approved generic is ready to enter the market.

This drug has two hundred and sixty-six patent family members in forty-six countries. There has been litigation on patents covering ESBRIET

See drug price trends for ESBRIET.

The generic ingredient in ESBRIET is pirfenidone. There are twenty-three drug master file entries for this API. Twenty-four suppliers are listed for this generic product. Additional details are available on the pirfenidone profile page.

Generic name: benzgalantamine gluconate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: September 22, 2026
Generic Entry Controlled by: Canada Patent 2,623,114
Patent Title: AMPLIFICATEURS CHOLINERGIQUES DE PERMEABILITE DE LA BARRIERE SANG-CERVEAU AMELIOREE POUR LE TRAITEMENT DE MALADIES ACCOMPAGNEES D'UNE DEFICIENCE COGNITIVE (CHOLINERGIC ENHANCERS WITH IMPROVED BLOOD-BRAIN BARRIER PERMEABILITY FOR THE TREATMENT OF DISEASES ACCOMPANIED BY COGNITIVE IMPAIRMENT)

ZUNVEYL is a drug marketed by Alpha Cognition. There are three patents protecting this drug.

This drug has twenty-six patent family members in seventeen countries. There has been litigation on patents covering ZUNVEYL

The generic ingredient in ZUNVEYL is benzgalantamine gluconate. One supplier is listed for this generic product. Additional details are available on the benzgalantamine gluconate profile page.

Generic name: sotagliflozin
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: September 29, 2026
Generic Entry Controlled by: Canada Patent 2,664,688

INPEFA is a drug marketed by Lexicon Pharms Inc. There are three patents protecting this drug.

This drug has eighty-one patent family members in thirty-three countries.

See drug price trends for INPEFA.

The generic ingredient in INPEFA is sotagliflozin. One supplier is listed for this generic product. Additional details are available on the sotagliflozin profile page.

Generic name: lenalidomide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: October 03, 2026
Generic Entry Controlled by: Canada Patent 2,570,755
Patent Title: METHODES DE TRAITEMENT DE CERTAINES FORMES DE LEUCEMIE AU MOYEN DE 3-(4-AMINO-1-OXO-1,3-DIHYDRO-ISOINDOL-2-YL)-PIPERIDIN-2,6-DIONE (METHODS USING 3-(4-AMINO-1-OXO-1,3-DIHYDRO-ISOINDOL-2-YL)-PIPERIDINE-2,6-DIONE FOR TREATMENT OF CERTAIN LEUKEMIAS)

REVLIMID is a drug marketed by Bristol Myers Squibb. There are two patents protecting this drug and three Paragraph IV challenges.

This drug has three hundred and thirty-one patent family members in forty-one countries. There has been litigation on patents covering REVLIMID

See drug price trends for REVLIMID.

The generic ingredient in REVLIMID is lenalidomide. There are fourteen drug master file entries for this API. Nineteen suppliers are listed for this generic product. Additional details are available on the lenalidomide profile page.

Generic name: lenalidomide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: October 03, 2026
Generic Entry Controlled by: Canada Patent 2,972,299
Patent Title: METHODES DE TRAITEMENT DE CERTAINES FORMES DE LEUCEMIE AU MOYEN DE 3-(4-AMINO-1-OXO-1,3-DIHYDRO-ISOINDOL-2-YL)-PIPERIDIN-2,6-DIONE (METHODS USING 3-(4-AMINO-1-OXO-1,3-DIHYDRO-ISOINDOL-2-YL)-PIPERIDINE-2,6-DIONE FOR TREATMENT OF CERTAIN LEUKEMIAS)

REVLIMID is a drug marketed by Bristol Myers Squibb. There are two patents protecting this drug and three Paragraph IV challenges.

This drug has three hundred and thirty-one patent family members in forty-one countries. There has been litigation on patents covering REVLIMID

See drug price trends for REVLIMID.

The generic ingredient in REVLIMID is lenalidomide. There are fourteen drug master file entries for this API. Nineteen suppliers are listed for this generic product. Additional details are available on the lenalidomide profile page.

Generic name: abaloparatide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: October 03, 2026
Generic Entry Controlled by: Canada Patent 2,664,734
Patent Title: PROCEDE D'ADMINISTRATION PHARMACOLOGIQUE D'UNE PROTEINE ANABOLIQUE OSSEUSE (METHOD OF DRUG DELIVERY FOR BONE ANABOLIC PROTEIN)

TYMLOS is a drug marketed by Radius. There are nine patents protecting this drug.

This drug has fifty-six patent family members in twenty-nine countries. There has been litigation on patents covering TYMLOS

See drug price trends for TYMLOS.

The generic ingredient in TYMLOS is abaloparatide. One supplier is listed for this generic product. Additional details are available on the abaloparatide profile page.

Generic name: olaparib
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: October 17, 2026
Generic Entry Controlled by: Canada Patent 2,664,275

LYNPARZA is a drug marketed by Astrazeneca. There are twelve patents protecting this drug. Three tentatively approved generics are ready to enter the market.

This drug has two hundred and fifty-four patent family members in fifty-two countries. There has been litigation on patents covering LYNPARZA

See drug price trends for LYNPARZA.

The generic ingredient in LYNPARZA is olaparib. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the olaparib profile page.

Generic name: olaparib
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: October 17, 2026
Generic Entry Controlled by: Canada Patent 2,875,147

LYNPARZA is a drug marketed by Astrazeneca. There are twelve patents protecting this drug. Three tentatively approved generics are ready to enter the market.

This drug has two hundred and fifty-four patent family members in fifty-two countries. There has been litigation on patents covering LYNPARZA

See drug price trends for LYNPARZA.

The generic ingredient in LYNPARZA is olaparib. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the olaparib profile page.

Generic name: cabotegravir sodium
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: October 26, 2026
Generic Entry Controlled by: Canada Patent 2,626,956
Patent Title: DERIVE DE CARBAMOYLPYRIDONE POLYCYCLIQUE AYANT UNE ACTIVITE D'INHIBITION SUR L'INTEGRASE DU VIH (POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING INHIBITORY ACTIVITY ON HIV INTEGRASE)

VOCABRIA is a drug marketed by Viiv Hlthcare. There are two patents protecting this drug.

This drug has one hundred and twenty-six patent family members in thirty-three countries.

The generic ingredient in VOCABRIA is cabotegravir sodium. One supplier is listed for this generic product. Additional details are available on the cabotegravir sodium profile page.

Generic name: sacubitril; valsartan
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: November 08, 2026
Generic Entry Controlled by: Canada Patent 2,590,511
Patent Title: COMBINAISON PHARMACEUTIQUES D'UN ANTAGONISTE DE RECEPTEUR D'ANGIOTENSINE ET D'UN INHIBITEUR DE NEP (PHARMACEUTICAL COMBINATIONS OF AN ANGIOTENSIN RECEPTOR ANTAGONIST AND AN NEP INHIBITOR)

ENTRESTO SPRINKLE is a drug marketed by Novartis. There are three patents protecting this drug.

This drug has one hundred and eight patent family members in thirty-nine countries. There has been litigation on patents covering ENTRESTO SPRINKLE

See drug price trends for ENTRESTO SPRINKLE.

The generic ingredient in ENTRESTO SPRINKLE is sacubitril; valsartan. There are eleven drug master file entries for this API. Twenty-four suppliers are listed for this generic product. Additional details are available on the sacubitril; valsartan profile page.

Generic name: difelikefalin acetate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: November 10, 2026
Generic Entry Controlled by: Canada Patent 2,667,155

KORSUVA is a drug marketed by Vifor Intl. There are twelve patents protecting this drug.

This drug has fifty-three patent family members in twenty-seven countries. There has been litigation on patents covering KORSUVA

See drug price trends for KORSUVA.

The generic ingredient in KORSUVA is difelikefalin acetate. One supplier is listed for this generic product. Additional details are available on the difelikefalin acetate profile page.

Generic name: difelikefalin acetate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: November 10, 2026
Generic Entry Controlled by: Canada Patent 2,667,460

KORSUVA is a drug marketed by Vifor Intl. There are twelve patents protecting this drug.

This drug has fifty-three patent family members in twenty-seven countries. There has been litigation on patents covering KORSUVA

See drug price trends for KORSUVA.

The generic ingredient in KORSUVA is difelikefalin acetate. One supplier is listed for this generic product. Additional details are available on the difelikefalin acetate profile page.

Generic name: difelikefalin acetate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: November 10, 2026
Generic Entry Controlled by: Canada Patent 2,898,514

KORSUVA is a drug marketed by Vifor Intl. There are twelve patents protecting this drug.

This drug has fifty-three patent family members in twenty-seven countries. There has been litigation on patents covering KORSUVA

See drug price trends for KORSUVA.

The generic ingredient in KORSUVA is difelikefalin acetate. One supplier is listed for this generic product. Additional details are available on the difelikefalin acetate profile page.

Generic name: crizotinib
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: November 23, 2026
Generic Entry Controlled by: Canada Patent 2,632,283

XALKORI is a drug marketed by Pf Prism Cv. There are three patents protecting this drug.

This drug has one hundred and five patent family members in forty-six countries.

See drug price trends for XALKORI.

The generic ingredient in XALKORI is crizotinib. One supplier is listed for this generic product. Additional details are available on the crizotinib profile page.

Generic name: fluciclovine f-18
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: November 28, 2026
Generic Entry Controlled by: Canada Patent 2,629,227
Patent Title: COMPOSE PRECURSEUR DE COMPOSE ORGANIQUE MARQUE A L'HALOGENE RADIOACTIF (PRECURSOR COMPOUND OF RADIOACTIVE HALOGEN LABELED ORGANIC COMPOUND)

AXUMIN is a drug marketed by Blue Earth. There are eight patents protecting this drug.

This drug has thirty patent family members in sixteen countries. There has been litigation on patents covering AXUMIN

The generic ingredient in AXUMIN is fluciclovine f-18. One supplier is listed for this generic product. Additional details are available on the fluciclovine f-18 profile page.

Generic name: ganaxolone
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: November 28, 2026
Generic Entry Controlled by: Canada Patent 2,631,233

ZTALMY is a drug marketed by Marinus. There are eleven patents protecting this drug.

This drug has forty-eight patent family members in sixteen countries. There has been litigation on patents covering ZTALMY

See drug price trends for ZTALMY.

The generic ingredient in ZTALMY is ganaxolone. One supplier is listed for this generic product. Additional details are available on the ganaxolone profile page.

Generic name: suvorexant
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: December 01, 2026
Generic Entry Controlled by: Canada Patent 2,670,892

BELSOMRA is a drug marketed by Merck Sharp Dohme. There are three patents protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has seventy-five patent family members in thirty-six countries.

See drug price trends for BELSOMRA.

The generic ingredient in BELSOMRA is suvorexant. One supplier is listed for this generic product. Additional details are available on the suvorexant profile page.

Generic name: betrixaban
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: December 08, 2026
Generic Entry Controlled by: Canada Patent 2,671,502

BEVYXXA is a drug marketed by Portola Pharms Inc. There are five patents protecting this drug.

This drug has sixty-seven patent family members in twenty-six countries. There has been litigation on patents covering BEVYXXA

See drug price trends for BEVYXXA.

The generic ingredient in BEVYXXA is betrixaban. Additional details are available on the betrixaban profile page.

Generic name: betrixaban
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: December 08, 2026
Generic Entry Controlled by: Canada Patent 2,913,963

BEVYXXA is a drug marketed by Portola Pharms Inc. There are five patents protecting this drug.

This drug has sixty-seven patent family members in twenty-six countries. There has been litigation on patents covering BEVYXXA

See drug price trends for BEVYXXA.

The generic ingredient in BEVYXXA is betrixaban. Additional details are available on the betrixaban profile page.

Generic name: telotristat etiprate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: December 12, 2026
Generic Entry Controlled by: Canada Patent 2,672,233

XERMELO is a drug marketed by Tersera. There are five patents protecting this drug.

This drug has seventy patent family members in twenty-nine countries.

See drug price trends for XERMELO.

The generic ingredient in XERMELO is telotristat etiprate. One supplier is listed for this generic product. Additional details are available on the telotristat etiprate profile page.

Generic name: ingenol mebutate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: December 18, 2026
Generic Entry Controlled by: Canada Patent 2,634,073
Patent Title: COMPOSITIONS THERAPEUTIQUES (THERAPEUTIC COMPOSITIONS COMPRISING INGENOL-3-ANGELATE)

PICATO is a drug marketed by Leo Labs. There are twelve patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has thirty-five patent family members in twenty-one countries. There has been litigation on patents covering PICATO

See drug price trends for PICATO.

The generic ingredient in PICATO is ingenol mebutate. There are three drug master file entries for this API. Additional details are available on the ingenol mebutate profile page.

Generic name: aminolevulinic acid hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: December 22, 2026
Generic Entry Controlled by: Canada Patent 2,670,715
Patent Title: NANOEMULSION (NANOEMULSION)

AMELUZ is a drug marketed by Biofrontera. There are three patents protecting this drug.

This drug has thirty-one patent family members in eighteen countries.

See drug price trends for AMELUZ.

The generic ingredient in AMELUZ is aminolevulinic acid hydrochloride. There are six drug master file entries for this API. Four suppliers are listed for this generic product. Additional details are available on the aminolevulinic acid hydrochloride profile page.

Generic name: ferric citrate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: January 26, 2027
Generic Entry Controlled by: Canada Patent 2,640,763
Patent Title: METHODE PERMETTANT D'INVERSER, DE PREVENIR, DE RETARDER OU DE STABILISER LA CALCIFICATION DES TISSUS MOUS (METHOD OF REVERSING, PREVENTING, DELAYING OR STABILIZING SOFT TISSUE CALCIFICATION)

AURYXIA is a drug marketed by Keryx Biopharms. There are three patents protecting this drug.

This drug has one hundred and twenty-two patent family members in twenty-three countries. There has been litigation on patents covering AURYXIA

See drug price trends for AURYXIA.

The generic ingredient in AURYXIA is ferric citrate. There are twenty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the ferric citrate profile page.

Generic name: ferric citrate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: January 26, 2027
Generic Entry Controlled by: Canada Patent 2,640,974
Patent Title: METHODE DE TRAITEMENT DE NEPHROPATHIE CHRONIQUE (METHOD OF TREATING CHRONIC KIDNEY DISEASE)

AURYXIA is a drug marketed by Keryx Biopharms. There are three patents protecting this drug.

This drug has one hundred and twenty-two patent family members in twenty-three countries. There has been litigation on patents covering AURYXIA

See drug price trends for AURYXIA.

The generic ingredient in AURYXIA is ferric citrate. There are twenty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the ferric citrate profile page.

Generic name: alogliptin benzoate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 01, 2027
Generic Entry Controlled by: Canada Patent 2,677,193
Patent Title: PREPARATION DE COMPRIME NE PROVOQUANT PAS DE PROBLEME DE PASTILLAGE (TABLET PREPARATION WITHOUT CAUSING A TABLETING TROUBLE)

NESINA is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market.

This drug has sixty-nine patent family members in thirty-seven countries. There has been litigation on patents covering NESINA

See drug price trends for NESINA.

The generic ingredient in NESINA is alogliptin benzoate. There are ten drug master file entries for this API. Five suppliers are listed for this generic product. Additional details are available on the alogliptin benzoate profile page.

Generic name: alogliptin benzoate; pioglitazone hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 01, 2027
Generic Entry Controlled by: Canada Patent 2,677,201

OSENI is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug.

This drug has one hundred and one patent family members in forty-two countries. There has been litigation on patents covering OSENI

See drug price trends for OSENI.

The generic ingredient in OSENI is alogliptin benzoate; pioglitazone hydrochloride. There are ten drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the alogliptin benzoate; pioglitazone hydrochloride profile page.

Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 20, 2027
Generic Entry Controlled by: Canada Patent 2,677,989

PANCREAZE is a drug marketed by

This drug has one hundred and one patent family members in forty-two countries.

See drug price trends for PANCREAZE.

The generic ingredient in PANCREAZE is pancrelipase (amylase;lipase;protease). There are six drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.

Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 20, 2027
Generic Entry Controlled by: Canada Patent 2,677,989

ZENPEP is a drug marketed by

This drug has one hundred and one patent family members in forty-two countries.

See drug price trends for ZENPEP.

The generic ingredient in ZENPEP is pancrelipase (amylase;lipase;protease). There are six drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.

Generic name: amphetamine
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 15, 2027
Generic Entry Controlled by: Canada Patent 2,645,855
Patent Title: FORMULATIONS A LIBERATION MODIFIEE CONTENANT DES COMPLEXES MEDICAMENT - RESINE ECHANGEUSE D'IONS (MODIFIED RELEASE FORMULATIONS CONTAINING DRUG-ION EXCHANGE RESIN COMPLEXES)

DYANAVEL XR is a drug marketed by Tris Pharma Inc. There are eleven patents protecting this drug. Two tentatively approved generics are ready to enter the market.

This drug has twenty-one patent family members in fourteen countries. There has been litigation on patents covering DYANAVEL XR

See drug price trends for DYANAVEL XR.

The generic ingredient in DYANAVEL XR is amphetamine. There are fifty-five drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the amphetamine profile page.

Generic name: lefamulin acetate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 20, 2027
Generic Entry Controlled by: Canada Patent 2,678,795

XENLETA is a drug marketed by Hong Kong. There are four patents protecting this drug.

This drug has one hundred and twenty patent family members in thirty-six countries. There has been litigation on patents covering XENLETA

See drug price trends for XENLETA.

The generic ingredient in XENLETA is lefamulin acetate. Additional details are available on the lefamulin acetate profile page.

Generic name: rolapitant hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 22, 2027
Generic Entry Controlled by: Canada Patent 2,681,465

VARUBI is a drug marketed by Tersera. There are eight patents protecting this drug.

This drug has one hundred and fifty-eight patent family members in thirty-five countries.

The generic ingredient in VARUBI is rolapitant hydrochloride. One supplier is listed for this generic product. Additional details are available on the rolapitant hydrochloride profile page.

Generic name: florbetapir f-18
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 26, 2027
Generic Entry Controlled by: Canada Patent 2,644,530

AMYVID is a drug marketed by Avid Radiopharms Inc. There are two patents protecting this drug.

This drug has fifty-one patent family members in thirty-three countries. There has been litigation on patents covering AMYVID

The generic ingredient in AMYVID is florbetapir f-18. One supplier is listed for this generic product. Additional details are available on the florbetapir f-18 profile page.

Generic name: azilsartan kamedoxomil
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 28, 2027
Generic Entry Controlled by: Canada Patent 2,681,143
Patent Title: COMPOSITION PHARMACEUTIQUE SOLIDE COMPRENANT UN DERIVE DE BENZIMIDAZOLE-7-CARBOXYLATE ET UN AGENT DE CONTROLE DU PH (SOLID PHARMACEUTICAL COMPOSITION COMPRISING A BENZIMIDAZOLE-7-CARBOXYLATE DERIVATIVE AND A PH CONTROL AGENT)

EDARBI is a drug marketed by Azurity. There is one patent protecting this drug.

This drug has twenty-one patent family members in seventeen countries. There has been litigation on patents covering EDARBI

See drug price trends for EDARBI.

The generic ingredient in EDARBI is azilsartan kamedoxomil. There are six drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the azilsartan kamedoxomil profile page.

Generic name: edoxaban tosylate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 29, 2027
Generic Entry Controlled by: Canada Patent 2,680,039

SAVAYSA is a drug marketed by Daiichi Sankyo Inc. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and one patent family members in thirty-four countries. There has been litigation on patents covering SAVAYSA

See drug price trends for SAVAYSA.

The generic ingredient in SAVAYSA is edoxaban tosylate. There are four drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the edoxaban tosylate profile page.

Generic name: enzalutamide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 29, 2027
Generic Entry Controlled by: Canada Patent 2,648,139
Patent Title: COMPOSES DE DIARYLTHIOHYDANTOINE ET LEUR UTILISATION DANS LE TRAITEMENT DE TROUBLES D'HYPERPROLIFERATION (DIARYL THIOHYDANTOIN COMPOUNDS AND THEIR USE IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS)

XTANDI is a drug marketed by Astellas. There are seven patents protecting this drug and one Paragraph IV challenge. Four tentatively approved generics are ready to enter the market.

This drug has one hundred and ninety-one patent family members in thirty-five countries. There has been litigation on patents covering XTANDI

See drug price trends for XTANDI.

The generic ingredient in XTANDI is enzalutamide. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the enzalutamide profile page.

Generic name: axitinib
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 05, 2027
Generic Entry Controlled by: Canada Patent 2,682,859

INLYTA is a drug marketed by Pf Prism Cv. There are three patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market.

This drug has ninety-seven patent family members in thirty countries. There has been litigation on patents covering INLYTA

See drug price trends for INLYTA.

The generic ingredient in INLYTA is axitinib. There are four drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the axitinib profile page.

Generic name: eltrombopag olamine
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: Canada Patent 2,685,831

PROMACTA is a drug marketed by Novartis. There are six patents protecting this drug and two Paragraph IV challenges.

This drug has one hundred and thirty-five patent family members in forty-one countries. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. There are three drug master file entries for this API. Nine suppliers are listed for this generic product. Additional details are available on the eltrombopag olamine profile page.

Generic name: migalastat hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 16, 2027
Generic Entry Controlled by: Canada Patent 2,652,553
Patent Title: DOSAGES BIOLOGIQUES POUR LE DIAGNOSTIC ET L'EVALUATION D'OPTIONS DE TRAITEMENT DE LA MALADIE DE FABRY (ASSAYS FOR DIAGNOSING AND EVALUATING TREATMENT OPTIONS FOR FABRY DISEASE)

GALAFOLD is a drug marketed by Amicus Therap Us. There are sixty-three patents protecting this drug.

This drug has two hundred and ninety patent family members in thirty-one countries. There has been litigation on patents covering GALAFOLD

The generic ingredient in GALAFOLD is migalastat hydrochloride. One supplier is listed for this generic product. Additional details are available on the migalastat hydrochloride profile page.

Generic name: pasireotide pamoate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 24, 2027
Generic Entry Controlled by: Canada Patent 2,683,935

SIGNIFOR LAR is a drug marketed by Recordati Rare. There are three patents protecting this drug.

This drug has two hundred and ninety patent family members in thirty-one countries.

See drug price trends for SIGNIFOR LAR.

The generic ingredient in SIGNIFOR LAR is pasireotide pamoate. One supplier is listed for this generic product. Additional details are available on the pasireotide pamoate profile page.